Skip to content

Cervical Cancer Screening in Madagascar Using Smartphone Photos and Mobile Telemedicine

Cervical Cancer Screening in Madagascar: Usability of Mobile Telemedicine for Detection of Precancerous Lesions From Smartphone Photos

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02693379
Enrollment
1041
Registered
2016-02-26
Start date
2015-02-28
Completion date
2015-11-30
Last updated
2016-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Precancer

Keywords

cervical cancer, HPV, VIA, screening, smartphone, telemedicine

Brief summary

The purpose of this study is to determine whether smartphone photos may assist health-care worker (on-site) and to evaluate the diagnostic reliability and accuracy of cervical examination with smartphone photos of VIA (D-VIA), on-site and off-site, compared with conventional VIA, for human papillomavirus (HPV) positive women.

Detailed description

Background: Cervical cancer is the leading cause of cancer death in females in Madagascar. In this country, a large-scale screening of precancerous lesions with cytology is hardly possible, because of the lack of specialists and infrastructures. Visual inspection of the cervix with application of 5% acetic acid (VIA) is an inexpensive alternative but very subjective since it depends on the examiner's experience. Mobile telemedicine is a very promising tool in order to assist non-expert health-care workers in rural area for cervical cancer screening. Objective: To assess if Smartphone may assist health-care worker (on-site) and to evaluate the diagnostic reliability and accuracy of cervical examination with smartphone photos of VIA (D-VIA) compared with conventional VIA, for women testing positive for human papillomavirus (HPV). Material and method: On-site health care workers will be trained in VIA. Prescreened HPV-positive women will be referred to VIA evaluation, during which digital images with a smartphone (D-VIA) will be taken for later evaluation by a VIA specialist in Geneva linked by telemedicine. Women with positive VIA results will be treated with cold coagulation if eligible. Histological results will be considered as gold standard. The results will be analyzed with Cohen's kappa coefficient, Mcnemar's test and Bonferroni's adjustment for multiple comparisons to assess the performance of D-VIA. Expected results: Based on the results of this project, the investigators will develop an educational training and quality assurance program for health providers for VIA and so contribute to a scaling-up of cervical cancer control. An appropriate triage by VIA will reduce not only an excessive referral rate but also an excessive treatment delay, giving the possibility of a screen (HPV), see (VIA/D-VIA), and treat program in a single or two visits.

Interventions

DEVICED-VIA

D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared. Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment.

Sponsors

Prof. Patrick Petignat
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

* 30-49 years * HPV-positive * Attending the cervical cancer screening program conducted by the Saint-Damien Health-Care Centre * Understands study procedures and accepts voluntarily to participate by signing the informed consent form (ICF)

Exclusion criteria

* Previous Hysterectomy * Conditions that can interfere with visualization of the cervix * Pregnancy \> 20 weeks * Not able to comply with protocol study.

Design outcomes

Primary

MeasureTime frameDescription
Differences in sensitivity and specificity of VIA examination (control) and digital VIA to detect cervical cancer and pre-cancerup to 12 monthsSensitivity and specificity will be calculated using histological results as gold-standard. All lesion Cin2 and worse will be considered as pathological.

Secondary

MeasureTime frame
Overall agreement between diagnoses based on VIA examination (control) and diagnoses for the same patient based on digital VIA.up to 12 months

Countries

Madagascar

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026